Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Abbott Laboratories, consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net earnings 1,594 1,436 1,375 1,318 1,033 1,435 2,018 2,447 1,989 2,100 1,189 1,793 2,162 1,232 537 564 1,049 960 1,006 672
Depreciation 332 328 302 315 311 317 315 311 369 327 370 425 358 298 272 267 273 270 268 267
Amortization of intangible assets 481 496 498 491 496 498 507 512 514 520 504 509 508 510 553 561 483 484 483 486
Share-based compensation 114 117 132 281 115 123 142 305 106 114 132 288 98 100 115 233 85 94 114 226
Net loss on extinguishment of debt 63
Trade receivables 68 (461) (196) 233 341 530 (188) (751) (189) (394) 35 165 (581) (470) 231 (104) 82 (22) (165) (170)
Inventories 295 140 (248) (419) (189) (194) (476) (554) 15 71 (5) (537) 345 149 (550) (437) 137 (190) (254) (286)
Other, net 154 (179) (660) (1,076) 219 71 92 (205) 263 (37) (97) (6) 908 247 164 (369) 244 352 (392) (483)
Adjustments to reconcile net earnings to net cash from operating activities 1,444 441 (172) (175) 1,293 1,345 392 (382) 1,078 601 939 844 1,636 834 785 151 1,367 988 54 40
Net cash from operating activities 3,038 1,877 1,203 1,143 2,326 2,780 2,410 2,065 3,067 2,701 2,128 2,637 3,798 2,066 1,322 715 2,416 1,948 1,060 712
Acquisitions of property and equipment (755) (560) (507) (380) (610) (467) (379) (321) (614) (461) (413) (397) (679) (496) (642) (360) (434) (401) (468) (335)
Acquisitions of businesses and technologies, net of cash acquired (51) (826) (172) (15) (10) (32) 1 (11) (82) (78)
Proceeds from business dispositions 40 48 86 48 10 48 48
(Purchases) sales of other investment securities, net (71) (38) 79 (86) (30) (21) 59 (41) (69) (108) 95 (14) (58) 17 4 (36) (60) (24) 2
Other 2 15 1 4 8 4 8 2 12 4 6 4 6 7 3 3 4 4 4 15
Net cash used in investing activities (824) (634) (1,213) (462) (632) (484) (264) (360) (671) (651) (264) (422) (731) (472) (619) (393) (489) (432) (498) (396)
Net borrowings (repayments) of short-term debt and other 111 (61) 13 (42) 10 24 5 8 (197) (27) (4) 24 (1) (28) (20) 51 (52) 12 27 13
Proceeds from issuance of long-term debt 1 1 1 6 4 1 1 1,279 1,842
Repayments of long-term debt (1,051) (1,445) (2) (1) (1) (751) (3) (40) (3) (2) (1) (1,330) (1) (1) (2,918) (2) (21) (500)
Purchases of common shares (259) (2) (426) (540) (685) (798) (5) (2,307) (974) (579) (471) (275) (161) (2) (4) (236) (496) (1) (4) (217)
Proceeds from stock options exercised 34 56 15 62 41 57 10 59 82 70 17 86 16 83 57 89 7 47 117 127
Dividends paid (888) (888) (890) (890) (823) (826) (828) (832) (798) (801) (803) (800) (641) (639) (642) (638) (568) (569) (568) (565)
Other (11)
Net cash used in financing activities (2,052) (2,340) (1,289) (1,410) (1,457) (1,543) (813) (3,823) (1,886) (1,377) (1,264) (967) (787) (1,915) 658 (735) (2,185) (513) (449) (1,142)
Effect of exchange rate changes on cash and cash equivalents 25 (29) (27) 8 51 (96) (71) (6) (13) (29) 4 (32) 78 38 25 (70) 27 (49) 2 4
Net increase (decrease) in cash and cash equivalents 187 (1,126) (1,326) (721) 288 657 1,262 (2,124) 497 644 604 1,216 2,358 (283) 1,386 (483) (231) 954 115 (822)

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Cash flow statement item Description The company
Net cash from operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Abbott Laboratories net cash from operating activities increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Net cash used in investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Abbott Laboratories net cash used in investing activities increased from Q2 2023 to Q3 2023 but then slightly decreased from Q3 2023 to Q4 2023.
Net cash used in financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Abbott Laboratories net cash used in financing activities decreased from Q2 2023 to Q3 2023 but then slightly increased from Q3 2023 to Q4 2023.